4R-Tau Protein
Overview <table class="infobox infobox-protein"> <tr> <th class="infobox-header" colspan="2">4R-Tau Protein</th> </tr> <tr> <td class="label">Symbol</td> <td><strong>4R-TAU</strong></td> </tr> <tr> <td class="label">Full Name</td> <td>4R-Tau</td> </tr> <tr> <td class="label">Type</td> <td>Protein</td> </tr> <tr> <td class="label">UniProt</td> <td><a href="https://www.uniprot.org/uniprot/?query=4R-TAU" target="_blank">Search UniProt</a></td> </tr> </table>
4R-Tau refers to the tau protein isoform containing four microtubule-binding repeat domains, encoded by the [MAPT](/genes/mapt) (Microtubule-Associated Protein Tau) gene. Tau exists as six isoforms in the adult human brain, generated by alternative splicing of exon 10. The 3R-Tau isoforms (3 repeats) and 4R-Tau isoforms (4 repeats) are normally expressed in a 1:1 ratio. Dysregulation leading to increased 4R-Tau production is a hallmark of several neurodegenerative diseases collectively called 4R-tauopathies[@buee2000].
The 4R-tauopathies include [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP), [Corticobasal Degeneration](/diseases/corticobasal-degeneration) (CBD), and certain forms of Alzheimer's disease. The presence of 4R-tau predominant pathology is a key diagnostic feature distinguishing these conditions from 3R-predominant diseases like Pick's disease[@dickson2010].
...
4R-Tau Protein
Overview <table class="infobox infobox-protein"> <tr> <th class="infobox-header" colspan="2">4R-Tau Protein</th> </tr> <tr> <td class="label">Symbol</td> <td><strong>4R-TAU</strong></td> </tr> <tr> <td class="label">Full Name</td> <td>4R-Tau</td> </tr> <tr> <td class="label">Type</td> <td>Protein</td> </tr> <tr> <td class="label">UniProt</td> <td><a href="https://www.uniprot.org/uniprot/?query=4R-TAU" target="_blank">Search UniProt</a></td> </tr> </table>
4R-Tau refers to the tau protein isoform containing four microtubule-binding repeat domains, encoded by the [MAPT](/genes/mapt) (Microtubule-Associated Protein Tau) gene. Tau exists as six isoforms in the adult human brain, generated by alternative splicing of exon 10. The 3R-Tau isoforms (3 repeats) and 4R-Tau isoforms (4 repeats) are normally expressed in a 1:1 ratio. Dysregulation leading to increased 4R-Tau production is a hallmark of several neurodegenerative diseases collectively called 4R-tauopathies[@buee2000].
The 4R-tauopathies include [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP), [Corticobasal Degeneration](/diseases/corticobasal-degeneration) (CBD), and certain forms of Alzheimer's disease. The presence of 4R-tau predominant pathology is a key diagnostic feature distinguishing these conditions from 3R-predominant diseases like Pick's disease[@dickson2010].
Protein Name: 4R-Tau - Tau Protein with Four Repeat Domains
UniProt ID: P10636 (isoform 2)
Gene: MAPT
Molecular Weight: ~45-65 kDa (depending on isoform)
Protein Class: Microtubule-associated protein
Tissue Expression: Neurons (axons), astrocytes, oligodendrocytes
Isoform Length: 383-441 amino acids (4R isoforms)
Molecular Structure 4R-tau isoforms contain[@mandelkow1995]:
N-terminal Region
N-terminal projection domain: Projects away from microtubules, interacts with neuronal membranes
Proline-rich region: Contains multiple phosphorylation sites (20+ ser/thr sites)
1N, 2N isoforms: Include N-terminal inserts from exon 2/3
Microtubule-Binding Domain
C-terminal microtubule-binding domain: Contains either 3 (3R-tau) or 4 (4R-tau) repeat regions
Repeat domains R1-R4: Each repeat is ~31 amino acids
PHF6 motif: Hexapeptide sequence essential for aggregation
4R-tau includes repeat R3: The additional repeat increases microtubule binding affinity
Exon 10 inclusion: Results in 4R-tau isoforms
Alternative splicing: Regulated by ASF/SF2 and SRRM2
Function Normal tau functions include[@weingarten1975]:
Microtubule Stabilization
Promotes tubulin polymerization and microtubule stability
Dynamic instability regulation
Axonal transport support
Axonal Transport
Facilitates vesicle and organelle movement along axons
Kinesin/dynactin interactions
Organelle positioning
Neuronal Polarity
Maintains axonal identity
Distinguishes axons from dendrites
Regulates synapse formation
Synaptic Function
Modulates synaptic vesicle trafficking
Presynaptic and postsynaptic roles
Activity-dependent regulation
Additional Functions
DNA protection under stress conditions
Signal transduction scaffolding
RNA metabolism support
3R vs 4R Balance The balance between 3R-tau and 4R-tau is critical[@vasquez2019]:
1:1 ratio in normal adult brain
4R-tau has ~2-fold higher microtubule binding affinity
Excess 4R leads to microtubule hyperstabilization
Role in Neurodegeneration
Progressive Supranuclear Palsy (PSP) PSP is the prototypical 4R-tauopathy[@dickson2010]:
Pathology
4R predominant: 4R-tau aggregates are the hallmark pathology
Glial tauopathy: Tau in astrocytes (tufted astrocytes) and oligodendrocytes
Neurofibrillary tangles: Composed of 4R-tau filaments
Brainstem involvement: Substantia nigra, brainstem nuclei
Molecular Mechanisms
Splicing dysregulation: Exon 10 inclusion increased
Aggregation propensity: 4R-tau forms paired helical filaments
Prion-like propagation: Seeding of tau pathology
Post-translational modifications: Hyperphosphorylation, acetylation
Clinical Features
Vertical gaze palsy
Postural instability
Parkinsonism
Cognitive decline
Corticobasal Degeneration (CBD) CBD is another 4R-tauopathy with distinct pathology:
Pathology
4R-tau pathology: Astrocytic plaques, thread-like processes
Neuronal loss: Cortical and basal ganglia involvement
Tau isoforms: Predominantly 4R-tau
Astrocytic plaques: Characteristic lesion
Molecular Features
Altered splicing: Increased 4R-tau
Specific mutations: Associated with CBD-causing MAPT mutations
Propagation: Spreading through neural networks
Alzheimer Disease AD shows mixed tau pathology with both 3R and 4R tau:
Pathology
Mixed pathology: Both 3R and 4R tau (AD-tau)
NFT formation: Paired helical filaments of mixed composition
Braak staging: Spread of pathology through brain
Tau PET: Imaging of tau aggregates
Splicing Changes
Age-related alterations in exon 10 splicing
Early changes in 3R/4R balance
Therapeutic target for splicing modulators
Therapeutic Potential
Splicing Modifiers
Compounds that reduce exon 10 inclusion (reduce 4R)
ASF/SF2 modulators
Antisense oligonucleotides
Aggregation Inhibitors
Prevent 4R-tau fibril formation
Small molecule inhibitors
Antibody-based approaches
Immunotherapy
Tau-targeting antibodies
Vaccines against tau
Active vs passive immunization
Key Publications
[Goedert M, et al, Tau isoforms in Alzheimer's disease (1991)](https://pubmed.ncbi.nlm.nih.gov/1909278/)
[Kidd M, et al, Paired helical filaments in progressive supranuclear palsy (1963)](https://pubmed.ncbi.nlm.nih.gov/14082178/)
[Mandelkow EM, et al, Tau domain organization and microtubule binding (1995)](https://pubmed.ncbi.nlm.nih.gov/7534762/)
[Weingarten MD, et al, Tau as a microtubule-associated protein (1975)](https://pubmed.ncbi.nlm.nih.gov/1057010/)
[Buée L, et al, Tau protein isoforms, phosphorylation and role in neurodegenerative disorders (2000)](https://pubmed.ncbi.nlm.nih.gov/11015108/)
[Dickson DW, et al, Neuropathology of 4R-tauopathies (2010)](https://pubmed.ncbi.nlm.nih.gov/20111842/)
[Combs B, et al, Tau oligomers in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31173764/)
[Vasquez VM, et al, Tau splicing and 4R-tauopathies (2019)](https://pubmed.ncbi.nlm.nih.gov/31212071/)
[Leger B, et al, Tau propagation and 4R-tauopathies (2018)](https://pubmed.ncbi.nlm.nih.gov/29580732/)
[Krestchev T, et al, Tau post-translational modifications in 4R-tauopathies (2020)](https://pubmed.ncbi.nlm.nih.gov/32216079/)
Cross-Links
[MAPT Gene](/genes/mapt) - Gene page
[Tau Protein](/proteins/tau) - Overview
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) - Disease
[Corticobasal Degeneration](/diseases/corticobasal-degeneration) - Disease
[Tauopathy Mechanisms](/mechanisms/tauopathy) - Pathway
References
[Goedert M, et al, Tau isoforms in Alzheimer's disease (1991)](https://pubmed.ncbi.nlm.nih.gov/1909278/)
[Kidd M, et al, Paired helical filaments in progressive supranuclear palsy (1963)](https://pubmed.ncbi.nlm.nih.gov/14082178/)
[Mandelkow EM, et al, Tau domain organization and microtubule binding (1995)](https://pubmed.ncbi.nlm.nih.gov/7534762/)
[Weingarten MD, et al, Tau as a microtubule-associated protein (1975)](https://pubmed.ncbi.nlm.nih.gov/1057010/)
[Buée L, et al, Tau protein isoforms, phosphorylation and role in neurodegenerative disorders (2000)](https://pubmed.ncbi.nlm.nih.gov/11015108/)
[Dickson DW, et al, Neuropathology of 4R-tauopathies (2010)](https://pubmed.ncbi.nlm.nih.gov/20111842/)
[Combs B, et al, Tau oligomers in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31173764/)
[Vasquez VM, et al, Tau splicing and 4R-tauopathies (2019)](https://pubmed.ncbi.nlm.nih.gov/31212071/)
[Leger B, et al, Tau propagation and 4R-tauopathies (2018)](https://pubmed.ncbi.nlm.nih.gov/29580732/)
[Krestchev T, et al, Tau post-translational modifications in 4R-tauopathies (2020)](https://pubmed.ncbi.nlm.nih.gov/32216079/)
See Also
[MAPT Gene](/genes/mapt)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Corticobasal Degeneration](/diseases/corticobasal-degeneration)
[Tauopathy Mechanisms](/mechanisms/tauopathy)
[Tau Protein](/proteins/tau)
[Microtubule Function](/mechanisms/microtubule-function)
External Links
[GeneCards: MAPT](https://www.genecards.org/cgi-bin/carddisp.pl?gene=MAPT)
[UniProt: P10636](https://www.uniprot.org/uniprot/P10636)
[Allen Human Brain Atlas](https://brain-map.org/) - Brain gene expression data for MAPT
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: AQP4
[Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
[Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: CERS2
[Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: C1QA
[Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: HSPG2
[Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: EPHB4
[Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: NTN1
Related Analyses:
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
Show full description